(Nevada, Las Vegas) United States, DelveInsight’s “Gene Therapy Competitive landscape, 2023” report provides comprehensive insights about 250+ companies and 300+ drugs in the CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gene Therapy TherapyPipeline Report
-
Leading Gene Therapy companies developing novel drug candidates are Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, and many others
-
Promising Gene Therapy pipeline therapies in various stages of development include BREYANZI, Valoctocogene Roxaparvovec, TILT-123, NG-347
Gene Therapy Overview
Gene Therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, Gene Therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient’s cells with a healthy version of that gene. Both inherited genetic diseases (e.g., hemophilia and sickle cell disease) and acquired disorders (e.g., leukemia) have been treated with Gene Therapy. Gene Therapy is the use of genetic material to treat or prevent disease. The genetic material that is delivered, DNA or RNA, has instructions to change how a protein—or group of proteins—is produced by the cell. For some diseases, this means making changes to account for too much, not enough, or incorrect essential proteins being produced within cells. This new genetic material, such as a working gene, is delivered into the cell using a vector. A vector is like a package used to deliver a specific message.
Discover more about the emerging Gene Therapy drugs @ GeneTherapy Treatment Drugs
Gene Therapy Pipeline Therapies and Key Companies
-
Juno Therapeutics: BREYANZI
-
BioMarin Pharmaceutical: Valoctocogene Roxaparvovec
-
Candel Therapeutics: CAN-2409
-
CRISPR Therapeutics: CTX001
And many others.
Scope of the Gene Therapy Pipeline Report
-
Coverage: Global
-
Key Gene Therapy Companies: Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals and many others.
-
Key Gene Therapy Pipeline Therapies: BREYANZI, Valoctocogene Roxaparvovec, CAN-2409, CTX001, and many others.
Find out more about the Gene Therapy treatment options in development @ CAR T – Cell Therapy Clinical Trials
Table of Contents
1 Introduction
2Executive Summary
3 Gene Therapy: Overview
3.1 Introduction
3.2Mechanism of Action
3.3Application
3.4Limitation
3.5Approved Therapies
4 GeneTherapy-Analytical Perspective: In-depth Commercial Assessment
4.1Gene Therapy Collaboration Analysis by Companies
Competitive Landscape
4.2Comparative Assessment of Companies (by therapy, development stage, and technology)
5Therapeutic Assessment
5.1Assessment by Product Type
5.2Assessment by Stage and Product Type
5.3Assessment by Route of Administration
5.4Assessment by Stage and Route of Administration
5.5Assessment by Molecule Type
5.6Assessment by Stage and Molecule Type
6 Gene Therapy: Company and Product Profiles (Marketed Therapies)
JW Therapeutics
6.1Company Overview
Relmacabtagene autoleucel
6.2Product Description
6.3Research and Development Activities
6.4Product Developmental Activities
7 GeneTherapy: Company and Product Profiles (Pipeline Therapies)
7.1Late Stage Products (Registered)
7.2Comparative Analysis
CARsgen
7.3Company Overview
Zevorcabtagene autoleucel
7.4Product Description
7.5Research and Development Activities
7.6Product Developmental Activities
Drug profiles in the detailed report…..
8Mid Stage Products (Phase II)
8.1Comparative Analysis
Cartesian Therapeutics
8.2Company Overview
Descartes 011
8.3Product Description
8.4Research and Development Activities
8.5Product Developmental Activities
Drug profiles in the detailed report…..
9Early Stage Products (Phase I)
9.1Comparative Analysis
Autolus Therapeutics
9.2Company Overview
AUTO-8
9.3Product Description
9.4Research and Development Activities
9.5Product Developmental Activities
Drug profiles in the detailed report…..
10Preclinical and Discovery Stage Products
10.1Comparative Analysis
Sana Biotechnology
10.2Company Overview
SG299
10.3Product Description
-
Research and Development Activities
10.4Product Developmental Activities
Drug profiles in the detailed report…..
10.5Products
-
Comparative Analysis
Gene Therapy – Unmet needs
Gene Therapy– Market drivers and barriers
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services